Galderma, a Swiss pharmaceutical giant, is capitalizing on the popularity of weight-loss drugs like Ozempic to boost its facial fillers business. The company has started a study to evaluate the effects of their products on patients who are using GLP-1 treatments like Ozempic. Enrollment for the study is ongoing and results may be available by the end of the year.
According to one cosmetic dermatologist, the Ozempic face is a result of aging and rapid weight loss which can lead to a sunken-in look in patients’ faces. Dr. Joshua Zeichner, a dermatologist, has stated that he sees patients with complaints of the Ozempic face almost daily due to the widespread use of medications like Ozempic. Cosmetic dermatologist Dr. Paul Jarrod Frank, who coined the term, explains that the Ozempic face is a result of aging and rapid weight loss.
Galderma creates skin care treatments and has products like Sculptra that are designed to counteract the gaunt look associated with the Ozempic face. Last month, Galderma went public on the SIX Swiss Exchange and reported a surge in shares. The company also reported a 12.4% increase year-over-year in sales, reaching $1 billion in the first quarter. With this new opportunity presented by the Ozempic face phenomenon, Galderma is looking forward to boosting its facial fillers business further in the future.
